In the international Acclaim trial, Celacade was shown to significantly reduce the risk of death or cardiovascular hospitalizations in large pre-specified subgroups of patients with chronic heart failure, including NYHA Class II patients, where risk was reduced by 39% and NYHA Class II to IV patients with no prior heart attack, where risk was reduced by 26%.
Vasogen said that the commercial introduction of Celacade in the EU will provide physicians and patients with a novel approach for the treatment of heart failure that is safe and well tolerated and can be used in combination with currently approved therapies for this condition.
Chris Waddick, president and CEO of Vasogen, said: “We look forward to continuing our close collaboration with Ferrer as we work to rapidly expand the use of Celacade within the EU.”